Category: Health Science
-
![Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin]()
Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin
Mushroom enthusiasts Filament Health (FH.NE) is looking at mushroom compounds far beyond just psilocybin as the company is run by actual mushroom enthusiasts with access to a lot of tools. Filament has the capabilities to experiment and come up with interesting new compounds, extraction methods, and potential future products that probably go far beyond whatever…
-
![Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering]()
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
![Xphyto (XPHY.C) partner/acquisition target achieves major milestone with Covid-19 biosensor candidates]()
Xphyto (XPHY.C) partner/acquisition target achieves major milestone with Covid-19 biosensor candidates
On July 28, 2021 Xphyto Therapeutics (XPHY.C) announced that its acquisition target, 3a-diagnostics GmbH, has identified the first saliva-activated in-mouth biosensor candidates for the detection of a COVID-19 infection. Xphyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. 3a-diagnostics is currently a commercial partner of…
-
![Diagnos (ADK.V) Announces Pilot with Opticalia in Spain]()
Diagnos (ADK.V) Announces Pilot with Opticalia in Spain
Diagnos (ADK.V), a leader in early detection announced today that it has signed a pilot in Spain with three franchisees from Opticalia Group. “The campaign begins with the request for a previous appointment through the web or at the optician itself, where patients will register in order of arrival and a free retinography will be…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
![Diagnos (ADK.V) opens A.I screening clinics in diabetes-ravaged Saudi Arabia]()
Diagnos (ADK.V) opens A.I screening clinics in diabetes-ravaged Saudi Arabia
On July 22, 2021 Diagnos (ADK.V) announced the official opening of the initial clinics at the Magrabi Hospital in Saudi Arabia. DIAGNOS specialises in early detection of health problems based on its FLAIRE artificial intelligence (AI) platform. The FLAIRE platform is used in applications such as CARA (Computer Assisted Retina Analysis). CARA’s artificial intelligence-based image…
-
![XPhyto Therapeutics (XPHY.C) Signs Acquisition Agreement with 3a-Diagnostics, Enters Biosensor Market]()
XPhyto Therapeutics (XPHY.C) Signs Acquisition Agreement with 3a-Diagnostics, Enters Biosensor Market
XPhyto Therapeutics (XPHY.C) announced today that it has signed a definitive agreement for the acquisition of 3a-Diagnostics GmhB, Frickenhausen, Germany, XPhyto’s exclusive diagnostic development partner. “We have collaborated closely with the 3a-diagnostics team on several diagnostics products and have found them to be a highly innovative and focused partner. The successful development and recent launch…
-
![Bioasis Technologies (BTI.V) stock is on the move – following scientific validation of xB3 platform]()
Bioasis Technologies (BTI.V) stock is on the move – following scientific validation of xB3 platform
Bioasis Technologies’ (BTI.V) xB3 platform is designed to deliver therapeutics across the blood brain barrier. BTI’s proprietary tech is relevant to the treatment of brain cancers and neurodegenerative diseases. Investing in small-cap pharmaceutical companies requires patience. Not every product in the pipeline pans out. Some trials have disappointing outcomes. Many investors can’t handle the zigs…
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
-
![Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?]()
Is it weird to talk about suicide, addiction and PTSD in the same breath as stonks and tendies?
“Suicide Opportunity” I can’t remember what company it was, maybe MindMed, but one of their early pitch decks had a page titled ‘Suicide Opportunity’. Yesterday I wrote an article outlining how Seelos Therapeutics was targetting suicide with ketamine-based treatments and it reminded me for a moment of that pitch deck. To note, Seelos didn’t word…
